WITHUS PHARMACEUTICAL Co.,LTD. (KOSDAQ:330350)
6,910.00
-50.00 (-0.72%)
At close: Oct 10, 2025
KOSDAQ:330350 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 102,494 | 102,722 | 80,119 | 64,680 | 57,419 | 53,406 | Upgrade |
Other Revenue | -0 | - | -0 | - | - | -0 | Upgrade |
102,494 | 102,722 | 80,119 | 64,680 | 57,419 | 53,406 | Upgrade | |
Revenue Growth (YoY) | 4.29% | 28.21% | 23.87% | 12.65% | 7.51% | 1.93% | Upgrade |
Cost of Revenue | 37,374 | 37,168 | 31,481 | 26,345 | 23,894 | 21,076 | Upgrade |
Gross Profit | 65,120 | 65,554 | 48,638 | 38,335 | 33,525 | 32,330 | Upgrade |
Selling, General & Admin | 56,255 | 56,002 | 37,237 | 29,767 | 26,100 | 22,699 | Upgrade |
Research & Development | 1,600 | 2,297 | 1,868 | 2,357 | 1,420 | 1,807 | Upgrade |
Other Operating Expenses | 181.93 | 178.61 | 186.67 | 278.07 | 296.44 | 202.68 | Upgrade |
Operating Expenses | 59,635 | 59,893 | 40,729 | 33,457 | 28,639 | 25,100 | Upgrade |
Operating Income | 5,485 | 5,661 | 7,909 | 4,878 | 4,886 | 7,230 | Upgrade |
Interest Expense | -788.53 | -814.08 | -596.06 | -390.74 | -323.96 | -229.23 | Upgrade |
Interest & Investment Income | 499.7 | 486.88 | 727.19 | 468.62 | 392.66 | 464.09 | Upgrade |
Currency Exchange Gain (Loss) | 1.68 | -3.18 | 1.72 | 0.63 | -3.98 | 6.57 | Upgrade |
Other Non Operating Income (Expenses) | 509.2 | 147.77 | -425.51 | -435.03 | -305.14 | -235.98 | Upgrade |
EBT Excluding Unusual Items | 5,707 | 5,478 | 7,617 | 4,521 | 4,646 | 7,236 | Upgrade |
Gain (Loss) on Sale of Investments | 1,053 | -133.97 | 1,515 | -373.86 | 979.32 | 520.11 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | 9.04 | 10.78 | -385 | 5.13 | Upgrade |
Asset Writedown | -205 | -205 | - | - | - | - | Upgrade |
Pretax Income | 6,554 | 5,139 | 9,141 | 4,158 | 5,240 | 7,761 | Upgrade |
Income Tax Expense | 574.32 | 354.3 | 1,182 | 1,679 | 976.07 | 1,109 | Upgrade |
Net Income | 5,980 | 4,785 | 7,959 | 2,479 | 4,264 | 6,652 | Upgrade |
Net Income to Common | 5,980 | 4,785 | 7,959 | 2,479 | 4,264 | 6,652 | Upgrade |
Net Income Growth | -21.85% | -39.88% | 221.04% | -41.86% | -35.91% | -17.24% | Upgrade |
Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 13 | 8 | Upgrade |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 13 | 8 | Upgrade |
Shares Change (YoY) | -0.39% | 0.00% | 0.09% | -0.10% | 59.55% | 6.63% | Upgrade |
EPS (Basic) | 453.69 | 362.49 | 603.00 | 188.00 | 323.00 | 804.02 | Upgrade |
EPS (Diluted) | 453.69 | 362.49 | 603.00 | 188.00 | 323.00 | 804.02 | Upgrade |
EPS Growth | -21.54% | -39.89% | 220.75% | -41.80% | -59.83% | -22.39% | Upgrade |
Free Cash Flow | 12,603 | 7,268 | -12,044 | -9,952 | 1,354 | -4,455 | Upgrade |
Free Cash Flow Per Share | 956.14 | 550.60 | -912.45 | -754.70 | 102.59 | -538.39 | Upgrade |
Gross Margin | 63.53% | 63.82% | 60.71% | 59.27% | 58.39% | 60.54% | Upgrade |
Operating Margin | 5.35% | 5.51% | 9.87% | 7.54% | 8.51% | 13.54% | Upgrade |
Profit Margin | 5.83% | 4.66% | 9.93% | 3.83% | 7.43% | 12.46% | Upgrade |
Free Cash Flow Margin | 12.30% | 7.07% | -15.03% | -15.39% | 2.36% | -8.34% | Upgrade |
EBITDA | 9,438 | 9,438 | 10,754 | 6,826 | 6,387 | 9,207 | Upgrade |
EBITDA Margin | 9.21% | 9.19% | 13.42% | 10.55% | 11.12% | 17.24% | Upgrade |
D&A For EBITDA | 3,953 | 3,778 | 2,844 | 1,948 | 1,501 | 1,977 | Upgrade |
EBIT | 5,485 | 5,661 | 7,909 | 4,878 | 4,886 | 7,230 | Upgrade |
EBIT Margin | 5.35% | 5.51% | 9.87% | 7.54% | 8.51% | 13.54% | Upgrade |
Effective Tax Rate | 8.76% | 6.89% | 12.93% | 40.38% | 18.63% | 14.29% | Upgrade |
Advertising Expenses | - | 832.52 | 841.87 | 831.45 | 887 | - | Upgrade |
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.